Monthly Galcanezumab Beneficial for Episodic Migraine Prevention
The researchers found that, compared to placebo, galcanezumab (120mg) significantly reduced migraine headache days (99.6% posterior probability, −4.8 days).
Migraine
Migraine Patch Product No Longer Available
Zecuity, launched in September 2015, is a transdermal system that delivers a therapeutic dose via a single-use, battery-powered patch wrapped around the upper arm or thigh.
BLA Submitted for Migraine Prevention Drug Fremanezumab
The studies looked at the safety, tolerability, and efficacy of 4 dose regimens of subcutaneous fremanezumab vs. placebo over 16 weeks.
Device for Migraine Prevention and Treatment Gets FDA Clearance
The non-invasive SpringTMS device is placed at the back of the patient’s head where a forced magnetic pulse is delivered to treat an acute attack or to prevent a future migraine onset.
CAM Use Among Migraine/Headache Sufferers Investigated
The use of complementary and alternative medicine (CAM) specifically for the treatment of migraine and headache is “relatively low” in the U.S.
Teva Launches Generic Relpax
Its agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
FDA: Migraine Patch May Cause Serious Burns, Scarring
Since September 2015, there have been numerous reports of burns or scars where the patch was applied.
Migraine Patient Information Fact Sheet
This patient information fact sheet provides information on the definition, symptoms, causes, treatments and self-help measures for migraines.
